Moreover, the TP53 gain-of-function (GOF) variant and mTOR pathway activation were predictive of worse survival and early progression in HPV-negative HNSCC patients (Niehr et al., 2018). This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.